ProJenX
Nissequogue, US · Founded 2021 · Delaware corporation · 9 employees on LinkedIn · 1 known investors
ProJenX is a clinical-stage biotechnology company developing novel, brain-penetrant therapies for neurodegenerative diseases, with an initial focus on amyotrophic lateral sclerosis (ALS). The company was created through a collaboration between nonprofit Project ALS, Medical Excellence Capital, and researchers at Columbia University to develop and commercialize therapeutic candidates including prosetin.
Founders & leadership
VE
Valerie EstessNamed on SEC filing
JE
Jenifer Estess
EL
Emily LowryDirector of Internal Operations at the Project ALS Therapeutics Core at Columbia
AZ
Arie ZaskFacility Manager for the Columbia University Chemical Probe Synthesis Facility
Board
JP
John PrufetainBoard directorChief Executive Officer and Managing Partner at Medical Excellence Capital
EH
JM
BR
Brent R. StockwellChair of the Department of Biological Science, Professor at Columbia University
HW
Hynek WichterleJerry and Emily Spiegel Professor at Columbia University
Investors · 1
Funding
SEC filings, press & company announcements$5.1M disclosed across 1 of 2 rounds · 2021–2023
- Undisclosed amountseries ANov 2023
Medical Excellence Capital (lead)
Source ↗
▶$5.1MraisedJan 2022 · 2 investors · BiotechnologyRule 506(b)
▶$5.1MraisedJan 2022 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John PrufetaDirector
- Eric HeilDirector
- Joni ManciniExecutive Officer
- Hynek WichterleDirector
- Valerie EstessDirector
- Offering amount
- $6M
- Amount sold
- $5.1M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapBioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Spinogenix4 shared keywordsSpinogenix is a biopharmaceutical company developing therapies to restore synaptic function, with a pipeline aimed at neurological and neurodegenerative conditions.
Predxbio3 shared keywordsPredxBio analyzes spatial multi-omic tissue data to identify response-defining biology, offering a decision-intelligence platform called SpaceIQ that supports drug development from discovery through clinical trials. It serves biopharma teams with biomarker strategy, patient stratification, and trial optimization insights.
Precigen3 shared keywordsPrecigen is a biopharmaceutical company developing gene and cell therapies, including PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis. The company focuses on immuno-oncology and immunotherapy treatments delivered via subcutaneous injection.
argenx3 shared keywordsargenx is an immunology company that operates an antibody innovation ecosystem where scientists and antibody engineers develop novel targets, disease pathways, and therapeutic antibodies. It builds a proprietary portfolio of first-in-class product candidates, engineered with academic partners, to translate immunology research into medicines for patients.
Companies competing with ProJenX for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does ProJenX do?
- ProJenX is a clinical-stage biotechnology company developing novel, brain-penetrant therapies for neurodegenerative diseases, with an initial focus on amyotrophic lateral sclerosis (ALS). The company was created through a collaboration between nonprofit Project ALS, Medical Excellence Capital, and researchers at Columbia University to develop and commercialize therapeutic candidates including prosetin.
- Who are ProJenX's investors?
- ProJenX's investors include Medical Excellence Capital.
- How much funding has ProJenX raised?
- ProJenX has disclosed $5.1M raised across 1 of its 2 known rounds.
- Where is ProJenX headquartered?
- ProJenX is headquartered in Nissequogue, US.